DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - General

Merck & Co., Inc.

MRKNYSE$145.27−$1.97 (−1.34%)Market closed

Price Chart

Daily

Key facts

Market Cap
$358.62B
P/E
19.7x
P/B
6.83x
ROE
36.9%

Merck & Co., Inc.

Healthcare · Drug Manufacturers - General · FY 2025

Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.

CEO
Mr. Robert M. Davis J.D.
Employees
73,000
Website
merck.com

Company Statistics

Valuation

P/E
19.7x
P/B
6.83x
P/S
5.53x
EV/EBITDA
13.5x
P/FCF
29.1x

Margins

Gross
74.8%
EBITDA
44.8%
Operating
34.0%
Pre-Tax
32.4%
Net
28.1%

Returns

ROA
14.4%
ROE
36.9%
ROIC
17.7%

Growth (CAGR)

Rev 3Yr
3.1%
Rev 5Yr
9.4%
Op Inc 3Yr
6.5%
Net Inc 3Yr
7.9%

Financial Health

Cash & Cash Equivalents
$14.57B
Net Debt
$69.64B
Debt/Equity
159.9%
Interest Cov
—

Profile

Revenue
$65.01B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Merck & Co., Inc. (MRK) Stock Forecast 2026 $145.27 — Price, Financials & Analyst Targets | AlphaLenz